Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
EBAG9 was identified as an estrogen-responsive gene. Additionally we are shipping Estrogen Receptor Binding Site Associated, Antigen, 9 Proteins (21) and Estrogen Receptor Binding Site Associated, Antigen, 9 Kits (5) and many more products for this protein.
Showing 10 out of 105 products:
Human Polyclonal EBAG9 Primary Antibody for WB - ABIN1881276
Wolf, Reimer, Schuck, Rüder, Gerlach, Müller, Otto, Dörken, Rehm: Role of EBAG9 protein in coat protein complex I-dependent glycoprotein maturation and secretion processes in tumor cells. in FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2010
Show all 5 Pubmed References
Bat Polyclonal EBAG9 Primary Antibody for WB - ABIN611293
Brocke, Chiang, Wagner, Schulman: Functional implications of the subunit composition of neuronal CaM kinase II. in The Journal of biological chemistry 1999
Show all 3 Pubmed References
Human Polyclonal EBAG9 Primary Antibody for ELISA, WB - ABIN251560
Rüder, Reimer, Delgado-Martinez, Hermosilla, Engelsberg, Nehring, Dörken, Rehm: EBAG9 adds a new layer of control on large dense-core vesicle exocytosis via interaction with Snapin. in Molecular biology of the cell 2005
Data suggest that joint detection of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) and carcinoembryonic antigen (CEA (show CEACAM5 Antibodies)) can improve the diagnostic sensitivity and specificity.
RCAS1 seems to be involved in creating tumor-induced inflammation in the tumor and its microenvironment
High EBAG9 expression is associated with malignant pleural effusion in patients with lung cancer.
Findings suggest that the histological effect of increased RCAS1 expression depends on its cellular source and that RCAS1 expression itself is a component of various signaling pathways in urothelial bladder cancer cells.
Given the significant correlation between tumor ADAM9 (show ADAM9 Antibodies) expression and serum RCAS1 concentration in both cervical and endometrial cancer as well as the role for ADAM9 (show ADAM9 Antibodies) in RCAS1 shedding.
suggests that RCAS1 has an apoptotic function via membranous/soluble expression pattern in OSCC cells. RCAS1 may thus affect tumor escape from immune surveillance in OSCC by inducing apoptosis
RCAS1 could be a useful immunohistochemical biomarker, indicating not only tumor aggressiveness but also a poorer prognosis for patients with NSCLC.
High EBAG9 expression is associated with tamoxifen resistance in breast cancer.
RCAS1 may play an important role in the phenomenon of tumor escape from host immunological surveillance and in creating the immune tolerance for the tumor cells, as well as in the tumor microenvironment.
The membrane molecule RCAS1 induces immune cell apoptosis via the RCAS1-RCAS1R pathway.
EBAG9 overexpression can be causative in enhancing the malignant properties of tumor cells.
In the RCAS1 siRNA group, blood pressure was raised whereas urine albumin (show ALB Antibodies)/creatinine ratio was increased. Our results suggest the importance of RCAS1 protein in the pathophysiologic condition of preeclampsia
findings show RCAS1 induced cytochrome c (show CYCS Antibodies) release & activation of caspase-3 (show CASP3 Antibodies) for apoptosis; cyclin D3 (show CCND3 Antibodies) decreased significantly; results suggest cyclin D3 (show CCND3 Antibodies) is one of key target molecules in RCAS1-RCAS1-R signaling pathway
In normal pregnant mice, RCAS1 protein mRNA was significantly increased on day 7.5 p.c. Antigen localization was detected in the placenta, decidua, and fetus.
EBAG9 may have a role in promoting progression of bladder cancer
EBAG9 promoted primary 4T1 mammary carcinoma growth and distant metastasis, and EBAG9 small interfering RNA exerted overt regression of tumor growth and metastasis
EBAG9 is a tunable inhibitor of CTL-mediated adaptive immune response functions.
This gene was identified as an estrogen-responsive gene. Regulation of transcription by estrogen is mediated by estrogen receptor which binds to the estrogen-responsive element (ERE) found in the 5'-flanking region of this gene. The encoded protein is a tumor-associated antigen that is expressed at high frequency in a variety of cancers. Two transcript variants differing in the 5' UTR, but encoding the same protein, have been identified for this gene.
estrogen receptor binding site associated, antigen, 9
, receptor-binding cancer antigen expressed on SiSo cells
, estrogen receptor binding site associated antigen 9
, estrogen receptor-binding fragment-associated gene 9
, receptor-binding cancer antigen expressed on siso cells
, cancer-associated surface antigen RCAS1
, estrogen receptor-binding fragment-associated gene 9 protein